CN115298218A - 生物药物组合物和相关方法 - Google Patents

生物药物组合物和相关方法 Download PDF

Info

Publication number
CN115298218A
CN115298218A CN202080094093.2A CN202080094093A CN115298218A CN 115298218 A CN115298218 A CN 115298218A CN 202080094093 A CN202080094093 A CN 202080094093A CN 115298218 A CN115298218 A CN 115298218A
Authority
CN
China
Prior art keywords
seq
composition
variant
antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080094093.2A
Other languages
English (en)
Chinese (zh)
Inventor
K.尼伦
M.张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texano Ltd
Original Assignee
Texano Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texano Ltd filed Critical Texano Ltd
Publication of CN115298218A publication Critical patent/CN115298218A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080094093.2A 2019-12-18 2020-12-10 生物药物组合物和相关方法 Pending CN115298218A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962949696P 2019-12-18 2019-12-18
US62/949,696 2019-12-18
US201962950595P 2019-12-19 2019-12-19
US62/950,595 2019-12-19
PCT/US2020/064241 WO2021126657A1 (en) 2019-12-18 2020-12-10 Biopharmaceutical compositions and related methods

Publications (1)

Publication Number Publication Date
CN115298218A true CN115298218A (zh) 2022-11-04

Family

ID=74125707

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080094093.2A Pending CN115298218A (zh) 2019-12-18 2020-12-10 生物药物组合物和相关方法

Country Status (11)

Country Link
US (1) US20230059341A1 (https=)
EP (1) EP4077388A1 (https=)
JP (2) JP2023507981A (https=)
KR (1) KR20220129548A (https=)
CN (1) CN115298218A (https=)
AU (2) AU2020407007A1 (https=)
BR (1) BR112022014694A2 (https=)
CA (1) CA3164600A1 (https=)
IL (1) IL293753A (https=)
MX (1) MX2022007464A (https=)
WO (1) WO2021126657A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4076385T1 (sl) * 2019-12-20 2026-04-30 Formycon Ag Formulacije protiteles anti-pd1
WO2024118587A1 (en) * 2022-11-30 2024-06-06 Tesaro, Inc. Methods of treating cancer with anti-pd-1-antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110049777A (zh) * 2016-11-01 2019-07-23 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
CN110382545A (zh) * 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
KR20180037275A (ko) * 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
CN106999591B (zh) * 2015-09-28 2021-02-23 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体制剂及其在医药上的应用
LT3386541T (lt) * 2015-12-07 2020-10-26 Merck Patent Gmbh Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110049777A (zh) * 2016-11-01 2019-07-23 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
CN110382545A (zh) * 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
吴霖萍: "治疗性单克隆抗体的理化特性分析平台的建立与应用", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》, vol. 2019, no. 4, 15 April 2018 (2018-04-15), pages 079 - 125 *
王辰等: "抗体异质性对抗体药物功能和代谢影响的研究进展", 《中国药科大学学报》, vol. 48, no. 5, 25 October 2017 (2017-10-25), pages 614 - 621 *

Also Published As

Publication number Publication date
AU2025203823A1 (en) 2025-06-19
JP2023507981A (ja) 2023-02-28
IL293753A (en) 2022-08-01
EP4077388A1 (en) 2022-10-26
AU2020407007A1 (en) 2022-06-23
CA3164600A1 (en) 2021-06-24
MX2022007464A (es) 2022-06-27
WO2021126657A1 (en) 2021-06-24
JP2026027328A (ja) 2026-02-18
US20230059341A1 (en) 2023-02-23
BR112022014694A2 (pt) 2022-09-06
KR20220129548A (ko) 2022-09-23

Similar Documents

Publication Publication Date Title
TWI791519B (zh) 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
EP3116911B1 (en) Anti-mcam (cd146, muc16) antibodies and associated methods of use
TWI761869B (zh) 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
US20150259419A1 (en) Anti-MCAM Antibodies and Associated Methods of Use
JP2020504141A (ja) 抗ｐｄ−１抗体を用いてがんを処置する方法
CN115969970A (zh) Abcg2抑制剂与sacituzumab govitecan的组合
JP2026027328A (ja) 生物医薬組成物および関連の方法
WO2017149513A1 (en) Anti-mcam antibodies and associated methods of use
WO2017208210A1 (en) Anti-mcam antibodies and associated methods of use
JP2023510928A (ja) 抗ｂｔｌａ抗体医薬組成物及びその使用
HK40083648A (zh) 生物藥物組合物和相關方法
US20250340643A1 (en) Anti-CTLA Antibody Compositions and Related Methods
TW202330027A (zh) 抗ｃｄ－４７抗體製劑
BR122024025522A2 (pt) Composições biofarmacêuticas, formulação, dispositivo de injeção, meio de cultura celular e eluato que compreendem as ditas composições e usos terapêuticos das mesmas
CN118946583A (zh) 用t细胞接合分子治疗前列腺癌的联合治疗方法
CA3226432A1 (en) Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab
WO2025130921A1 (en) Formulation comprising anti-claudin18.2 antibody
HK1233282A1 (en) Anti-mcam antibodies and associated methods of use
HK1233282B (en) Anti-mcam antibodies and associated methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083648

Country of ref document: HK